Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in developing small molecule therapeutics aimed at addressing significant unmet medical needs, particularly in oncology. The company is currently in a stable condition, reporting an increase in operating expenses and net losses year-over-year.

For the fourth quarter of 2024, Enliven reported a total net loss of $23.2 million, compared to a net loss of $19.4 million for the same period in 2023. For the full year 2024, the total net loss was $89.0 million, an increase from $71.6 million in 2023.

Research and development (R&D) expenses totaled $20.7 million in the fourth quarter of 2024, rising from $17.9 million a year earlier. For the full year 2024, R&D expenses were $80.8 million, which compares to $64.6 million for 2023. General and administrative (G&A) expenses for the fourth quarter were $6.2 million, an increase from $4.8 million in the fourth quarter of 2023. In total, G&A expenses for 2024 amounted to $23.8 million, up from $19.0 million in 2023.

Total operating expenses in the fourth quarter of 2024 were $26.9 million, compared to $22.7 million in the same quarter of 2023. For the full year, total operating expenses increased to $104.6 million, compared with $83.5 million in 2023.

As of December 31, 2024, Enliven had cash, cash equivalents, and marketable securities amounting to $313.4 million, up from $253.1 million as of December 31, 2023. This strong balance sheet supports a cash runway expected to extend into mid-2027.

The company reported a net loss per share of $0.46 for the fourth quarter of 2024, slightly improved from a loss of $0.47 per share in the fourth quarter of 2023. For the full year, the net loss per share was $1.89, down from $2.01 in 2023. The weighted average shares outstanding increased from 41.1 million in 2023 to 49.9 million in the fourth quarter of 2024.

Total current assets were $318.1 million, compared to $266.2 million for the previous year. Current liabilities for Enliven stood at $15.9 million, down from $25.9 million in 2023. Stockholders’ equity increased to $309.8 million from $245.9 million year over year.